secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2021-11-17T23:59:59+00:00
Accession:  0001193125-21-331813
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen R&D head Alfred Sandrock to retire Dec 31, 2021; interim named
---------------------------------------------------------------------

- Alfred W. Sandrock, Head of R&D, will retire effective Dec 31, 2021, after 23 years at Biogen.
- Priya Singhal, Head of Global Safety & Regulatory Sciences, will serve as interim R&D head.
- Sandrock led development of key drugs: Tysabri, Tecfidera, Spinraza, Plegridy, and Aduhelm.
- Biogen has launched a search for a permanent successor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000119312521331813/0001193125-21-331813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000119312521331813/d257656d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-331813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer